Evofem’s PHEXX® Receives Pricing Certificates in UAE, Paving Way for Launch

Evofem's PHEXX® Receives Favorable Pricing Certificates in UAE

Evofem Biosciences, a leader in women’s health, is poised to make significant strides in the UAE's healthcare market with the recent issuance of favorable pricing certificates for its innovative contraceptive product, PHEXX®. This milestone, announced on November 21, 2025, by Evofem, signifies an important step towards obtaining regulatory approval from the Emirates Drug Establishment (EDE) and sets the stage for a commercial launch in 2026.

What is PHEXX®?

PHEXX®, a hormone-free vaginal gel containing lactic acid, citric acid, and potassium bitartrate, is the first of its kind that acts locally to maintain a natural vaginal microbiome, creating an environment that is not favorable to sperm. The gel is applied shortly before intercourse using a pre-filled applicator, making it a practical option for women seeking on-demand contraceptive solutions without the side effects associated with hormonal methods.

Strategic Expansion Into Middle Eastern Markets

The approval and subsequent launch of PHEXX® in the UAE represent not only an expansion for Evofem but also provide Emirati women with greater access to safe contraceptive methods. Saundra Pelletier, CEO of Evofem, expressed enthusiasm regarding this development, highlighting how it diversifies the company’s revenue streams and enhances healthcare options for women in the region.

Evofem's partnership with Pharma 1, which holds exclusive commercialization rights in the UAE and five other Gulf Cooperation Council (GCC) states, is central to this initiative. Pharma 1 plans to introduce PHEXX® to the UAE market shortly after receiving formal marketing approval, which is expected to significantly enhance access to women's health services in the region.

Ensuring Success in New Markets

Pharma 1 is committed to managing all distribution, marketing, pharmacovigilance, and other operational aspects for PHEXX® in the licensed territory. Founded in 2019, Pharma 1 has rapidly established itself as a key player in the healthcare sector of the GCC by responding to evolving health needs through scientifically-backed solutions. In light of their growing portfolio, they are also preparing to seek marketing approvals for PHEXX® and another Evofem product, SOLOSEC®, in additional Middle Eastern and North African countries.

The Importance of Women's Health Products

The introduction of PHEXX® aligns well with the global trend towards prioritizing women’s health and reproductive rights. As women seek more empowering and diverse contraceptive options, PHEXX® offers an innovative alternative that aligns with these aspirations, making it imperative for Pharma 1 and Evofem to create effective awareness and education campaigns alongside the product launch.

In essence, the favorable pricing certificates from the EDE mark a pivotal shift in the landscape of contraception in the UAE, heralding a future where women have better access to hormone-free options that align with their health beliefs and preferences. Both Evofem and Pharma 1’s efforts are a testament to the growing recognition of women’s health needs within the region, ultimately supporting a more healthy and informed community.

Conclusion

Evofem’s dedication to addressing unmet health needs for women, coupled with Pharma 1’s strategic commercialization approach, is expected to create a significant impact in the UAE and beyond. As both companies move forward with the launch of PHEXX®, they not only enhance access to critical healthcare solutions but also set a precedent for future innovations in women's health.